Offshore generics makers eye biosimilars

Chinese and Indian generics makers say they are on the verge of selling cheaper copies of complex biotech medicines. They may enter the market as soon as next year, thanks to huge investments in biotech plants. The New York Times anticipates a transformation of care for patients in much of the world in addition to a counterattack by Big Pharma. Story